Alla Chem, LLC Announces Start of Phase Ib Proof-Of-Concept Clinical Study of AVR560, an HCV entry inhibitor, for the Treatment of Chronic Hepatitis C Infection

Hallandale Beach, Fl –May 15, 2014 — Alla Chem, LLC, announces today start of phase 1b clinical study of AVR560, an investigational, orally bioavailable HCV entry inhibitor, currently in clinical development for the treatment of chronic HCV infection.

In this randomized, double-blind, placebo-controlled, multicentre study of safety, tolerability, pharmacokinetics and antiviral activity of AVR560 in HCV-infected patients, HCV- infected, treatment-naive subjects will be randomized to receive 100 or 150 mg AVR560 or placebo QD for 14 days (up to 10 subjects per cohort, drug:placebo ratio 4:1).

In a previous double-blind, placebo-controlled, single ascending oral dose study of AVR560 safety and tolerability in healthy volunteers, the drug was safe and well-tolerated. The pharmacokinetic analyses supported once daily dosing.

The final results of this 1b study of safety, tolerability, pharmacokinetics and antiviral activity of AVR560 will be presented in at a major scientific conference in second half of this year.

 

Read more about HCV Platform

Comments are closed.